Innovotech Subsidiary Receives NRC IRAP Funding to Develop Advanced Antimicrobial Testing for Medical Devices

Innovotech Inc. announced that its subsidiary, Innovotech Labs Corporation, will receive advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding supports the development of new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.

The new testing methods align with changes in international regulatory standards and medical device manufacturers’ needs in the areas of proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development started last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data.

Strengthening these capabilities will expand the Company’s service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively. “This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”

Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing. Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.

The funding from NRC IRAP underscores the growing importance of advanced antimicrobial testing in the medical device industry, as regulatory bodies increasingly require evidence of biofilm prevention and infection control. This development is significant for manufacturers seeking to bring safer devices to market and for patients who may benefit from reduced infection risks. The original press release is available at https://www.newmediawire.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Innovotech Subsidiary Receives NRC IRAP Funding to Develop Advanced Antimicrobial Testing for Medical Devices.

The post Innovotech Subsidiary Receives NRC IRAP Funding to Develop Advanced Antimicrobial Testing for Medical Devices appeared first on citybuzz.